Skip Nav Destination
Issues
15 May 2013
-
Cover Image
Cover Image
This image is taken from a bone metastasis in a patient with stage IV relapsed invasive CDH1 mutated lobular carcinoma of the breast. The tumor was negative for ERBB2 (HER2) amplification (FISH). The targeted next generation sequencing assay used in this study found an ERBB2-GRB7 putative gene fusion that has not been previously reported. The fusion retains the kinase domain of ERBB2 (uniprot.org) which suggests that it could result in ERBB2 activation. The 17q12-21 amplicon which includes both ERBB2 and GRB7 is frequently amplified in breast cancer and preclinical studies suggest that it may be a recombination hotspot. An expression screening study has reported that GRB7 can function as an ERBB2-dependent oncogene. GRB7 encodes an adaptor protein that interacts with ERBB2 and has been shown in a preclinical study to enhance its transformative capacity and increase ERBB2 phosphorylation in fibroblasts. For details, see the article by Ross and colleagues on page 2668 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
Molecular Pathways
CCR Focus
Human Cancer Biology
Author Choice
Relapsed Classic E-Cadherin (CDH1)–Mutated Invasive Lobular Breast Cancer Shows a High Frequency of HER2 (ERBB2) Gene Mutations
Jeffrey S. Ross; Kai Wang; Christine E. Sheehan; Ann B. Boguniewicz; Geoff Otto; Sean R. Downing; James Sun; Jie He; John A. Curran; Siraj Ali; Roman Yelensky; Doron Lipson; Gary Palmer; Vincent A. Miller; Philip J. Stephens
Cancer Therapy: Preclinical
Concomitant BRAF and PI3K/mTOR Blockade Is Required for Effective Treatment of BRAFV600E Colorectal Cancer
Erin M. Coffee; Anthony C. Faber; Jatin Roper; Mark J. Sinnamon; Gautam Goel; Lily Keung; Wei Vivian Wang; Loredana Vecchione; Veerle de Vriendt; Barbara J. Weinstein; Roderick T. Bronson; Sabine Tejpar; Ramnik J. Xavier; Jeffrey A. Engelman; Eric S. Martin; Kenneth E. Hung
Temozolomide-Mediated DNA Methylation in Human Myeloid Precursor Cells: Differential Involvement of Intrinsic and Extrinsic Apoptotic Pathways
Haiyan Wang; Shanbao Cai; Aaron Ernstberger; Barbara J. Bailey; Michael Z. Wang; Wenjing Cai; W. Scott Goebel; Magdalena B. Czader; Colin Crean; Attaya Suvannasankha; Inna Shokolenkoc; Glenn L. Wilson; Arthur R. Baluyut; Lindsey D. Mayo; Karen E. Pollok
Imaging, Diagnosis, Prognosis
Identification of Prognosis-Relevant Subgroups in Patients with Chemoresistant Triple-Negative Breast Cancer
Ke-Da Yu; Rui Zhu; Ming Zhan; Angel A. Rodriguez; Wei Yang; Stephen Wong; Andreas Makris; Brian D. Lehmann; Xi Chen; Ingrid Mayer; Jennifer A. Pietenpol; Zhi-Ming Shao; W. Fraser Symmans; Jenny C. Chang
Cancer Therapy: Clinical
Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
Anna Kanerva; Petri Nokisalmi; Iulia Diaconu; Anniina Koski; Vincenzo Cerullo; Ilkka Liikanen; Siri Tähtinen; Minna Oksanen; Raita Heiskanen; Saila Pesonen; Timo Joensuu; Tuomo Alanko; Kaarina Partanen; Leena Laasonen; Kalevi Kairemo; Sari Pesonen; Lotta Kangasniemi; Akseli Hemminki
Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2–Negative Advanced Breast Cancer That Progressed during or after Bevacizumab
Lee S. Schwartzberg; Kurt W. Tauer; Robert C. Hermann; Grace Makari-Judson; Claudine Isaacs; J. Thaddeus Beck; Virginia Kaklamani; Edward J. Stepanski; Hope S. Rugo; Wei Wang; Katherine Bell-McGuinn; Jeffrey J. Kirshner; Peter Eisenberg; Richard Emanuelson; Mark Keaton; Ellis Levine; Diana C. Medgyesy; Rubina Qamar; Alexander Starr; Sunhee Kwon Ro; Nathalie A. Lokker; Clifford A. Hudis
Neoadjuvant Chemotherapy with or without Zoledronic Acid in Early Breast Cancer—A Randomized Biomarker Pilot Study
Matthew C. Winter; Caroline Wilson; Stuart P. Syddall; Simon S. Cross; Alyson Evans; Christine E. Ingram; Ingrid J. Jolley; Matthew Q. Hatton; Jennifer V. Freeman; Stefano Mori; Ingunn Holen; Robert E. Coleman
Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors
Antonio Jimeno; Glen J. Weiss; Wilson H. Miller, Jr; Scott Gettinger; Bernard J.C. Eigl; Anne Lynne S. Chang; Joi Dunbar; Shannon Devens; Kerrie Faia; Georgios Skliris; Jeff Kutok; Karl D. Lewis; Raoul Tibes; William H. Sharfman; Robert W. Ross; Charles M. Rudin
Predictive Biomarkers and Personalized Medicine
Correction
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.